IMVT reports Q3 cash of $797.8M and updates IMVT-1402 timeline for 2026
Immunovant reported $797.8M in cash and non-GAAP losses, with key topline data for CLE and D2T RA expected in late 2026. Only 90% of data provided for the Non-GAAP net loss figure in exhibit991202686.htm.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day